Patents Assigned to The Scripps Research Institute
  • Patent number: 10407493
    Abstract: The invention provides a method for obtaining a broadly neutralizing antibody (bNab), including screening memory B cell cultures from a donor PBMC sample for neutralization activity against a plurality of HIV-1 species, cloning a memory B cell that exhibits broad neutralization activity; and rescuing a monoclonal antibody from that memory B cell culture. The resultant monoclonal antibodies are characterized by their ability to selectively bind epitopes from the Env proteins in native or monomeric form, as well as to inhibit infection of HIV-1 species from a plurality of clades. Compositions containing human monoclonal anti-HIV antibodies used for prophylaxis, diagnosis and treatment of HIV infection are provided. Methods for generating such antibodies by immunization using epitopes from conserved regions within the variable loops of gp120 are provided. Immunogens for generating anti-HIV1 bNAbs are also provided. Furthermore, methods for vaccination using suitable epitopes are provided.
    Type: Grant
    Filed: February 14, 2019
    Date of Patent: September 10, 2019
    Assignees: THERACLONE SCIENCES, INC., INTERNATIONAL AIDS VACCINE INITIATIVE, THE SCRIPPS RESEARCH INSTITUTE
    Inventors: Po-Ying Chan-Hui, Steven Frey, Ole Olsen, Jennifer Mitcham, Matthew Moyle, Sanjay K. Phogat, Dennis R. Burton, Laura Marjorie Walker, Pascal Raymond Georges Poignard, Wayne Koff, Melissa Danielle De Jean De St. Marcel Simek-Lemos, Stephen Kaminsky
  • Patent number: 10407488
    Abstract: The present application generally relates to methods to prevent or treat bleeding and/or hypocoagulation in an individual in need thereof, and compositions for use in such methods. The methods comprise administration of FVa, preferably an APC resistant FVa (such as superFVa), alone or in combination with FVIIa, preferably rhFVIIa (such as NovoSeven® or another FVIIa having enhanced activity or half-life). When administered in combination, FVa and FVIIa elicit a synergistic benefit when used to treat or prevent bleeding or hypocoagulation in subjects in need thereof, e.g.
    Type: Grant
    Filed: November 4, 2014
    Date of Patent: September 10, 2019
    Assignees: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE SCRIPPS RESEARCH INSTITUTE
    Inventors: John H. Griffin, Laurent Mosnier, Annette Von Drygalski, Andrew Gale
  • Patent number: 10391155
    Abstract: Disclosed herein are chimeric antigen receptor effector cells (CAR-ECs) and CAR-EC switches. The switchable CAR-ECs are generally T cells. The one or more chimeric antigen receptors may recognize a peptidic antigen on the CAR-EC switch. The CAR-ECs and switches may be used for the treatment of a condition in a subject in need thereof.
    Type: Grant
    Filed: March 2, 2017
    Date of Patent: August 27, 2019
    Assignee: THE SCRIPPS RESEARCH INSTITUTE
    Inventors: Travis Young, Chanhyuk Kim, Peter G. Schultz
  • Patent number: 10370409
    Abstract: The present disclosure is directed to a novel class of peptide-like oligomers called peptide tertiary amides (PTAs) and a combinatorial library of PTAs along with synthetic routes for the preparation of large combinatorial libraries of these compounds. The peptide tertiary amides provide an exceptional source of high affinity and selective protein ligands that are useful as tools for biological research and as drug leads, among others.
    Type: Grant
    Filed: October 25, 2012
    Date of Patent: August 6, 2019
    Assignee: The Scripps Research Institute
    Inventors: Thomas Kodadek, Yu Gao
  • Publication number: 20190218257
    Abstract: Disclosed herein are proteins, methods, cells, engineered microorganisms, and kits for generating a modified nucleoside triphosphate transporter from Phaeodactylum tricornutum. Also disclosed herein proteins, methods, cells, engineered microorganisms, and kits for production of a nucleic acid molecule that comprises an unnatural nucleotide utilizing a modified nucleoside triphosphate transporter from Phaeodactylum tricornutum.
    Type: Application
    Filed: June 23, 2017
    Publication date: July 18, 2019
    Applicant: The Scripps Research Institute
    Inventors: Floyd E. ROMESBERG, Yorke ZHANG
  • Patent number: 10351626
    Abstract: Methods, compositions and uses are provided for bispecific antibodies comprising one or more unnatural amino acids. The bispecific antibodies may bind to two or more different receptors, co-receptors, antigens, or cell markers on one or more cells. The bispecific antibodies may be used to treat a disease or condition (e.g., cancer, autoimmune disease, pathogenic infection, inflammatory disease). The bispecific antibodies may be used to modulate (e.g., stimulate or suppress) an immune response.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: July 16, 2019
    Assignee: The Scripps Research Institute
    Inventors: Chanhyuk Kim, Jun Y. Axup, Hwayoung Yun, Peter G. Schultz, Jennifer Ma, Jiayin Shen, Pengyu Yang
  • Patent number: 10351822
    Abstract: The present invention relates compounds for stabilizing cells and methods of their use.
    Type: Grant
    Filed: January 5, 2018
    Date of Patent: July 16, 2019
    Assignee: The Scripps Research Institute
    Inventors: Yue Xu, Sheng Ding
  • Patent number: 10342861
    Abstract: The invention relates to compositions and methods for preventing or treating arenavirus related diseases and disorders through the administration to a subject in need thereof a live-attenuated virus (LAV), wherein the LAV is a codon deoptimized (CD) arenavirus.
    Type: Grant
    Filed: May 27, 2015
    Date of Patent: July 9, 2019
    Assignees: UNIVERSITY OF ROCHESTER, THE SCRIPPS RESEARCH INSTITUTE
    Inventors: Luis Martinez-Sobrido, Juan Carlos De La Torre
  • Patent number: 10336735
    Abstract: Described herein are compounds and compositions for the treatment of a fibrotic disease.
    Type: Grant
    Filed: December 9, 2015
    Date of Patent: July 2, 2019
    Assignee: THE SCRIPPS RESEARCH INSTITUTE
    Inventors: Luke Lairson, Arnab K. Chatterjee, Michael Bollong, Baiyuan Yang, Peter G. Schultz
  • Patent number: 10336766
    Abstract: Enediyne compounds having a structure according to formula (I), where R1, R2, R3, R4, R5, R6, R7 and X are defined herein.
    Type: Grant
    Filed: January 8, 2016
    Date of Patent: July 2, 2019
    Assignee: The Scripps Research Institute
    Inventor: Ben Shen
  • Patent number: 10335420
    Abstract: An aqueous tumor-targeting liposome nanoparticle composition comprises an aqueous dispersion of liposome nanoparticles. The nanoparticles preferably encapsulate an anti-cancer chemotherapeutic agent, which can be added to a pre-formed liposome composition or can be incorporated in the liposomes during the formation of the liposomes. The liposome nanoparticles comprise a legumain-targeting lipid admixed with one or more other micelle or vesicle-forming lipid materials in the form of nanoparticulate liposomes dispersed in an aqueous carrier. A preferred tumor-targeting liposome nanoparticle composition comprises a legumain-targeting lipid component and polyethylene glycol-conjugated lipid component. The legumain-targeting lipid component comprising a hydrophobic lipid portion covalently attached to a legumain-binding moiety.
    Type: Grant
    Filed: April 24, 2017
    Date of Patent: July 2, 2019
    Assignee: The Scripps Research Institute
    Inventors: Ralph A. Reisfeld, Rong Xiang, Yunping Luo, Debbie Liao, Ze Liu, Tingmei Chen, Si Chen, Dan Lu
  • Patent number: 10328078
    Abstract: The invention provides compounds effective as inhibitors of monocarboxylate transporters such as MCT1 and MCT4, which can be used for treatment of medical conditions wherein treatment of the condition with a compound having an inhibitor effect on MCT1, MCT4, or both is medically indicated. Compounds of the invention can have antitumor, antidiabetes, anti-inflammatory, or immunosuppressive pharmacological effects, and can be effective for treatment of cancer and of type II diabetes.
    Type: Grant
    Filed: January 22, 2016
    Date of Patent: June 25, 2019
    Assignee: The Scripps Research Institute
    Inventors: Thomas D. Bannister, Hui Wang, Chao Wang, John L. Cleveland
  • Patent number: 10329303
    Abstract: The invention provides compounds that inhibit monocarboxylate transporters, such as MCT1 and MCT4. Compounds of the invention can be used for treatment of a condition in a patient, wherein the condition is characterized by the heightened activity or by the high prevalence of MCT1 and/or MCT4, such as cancer or type II diabetes.
    Type: Grant
    Filed: January 22, 2016
    Date of Patent: June 25, 2019
    Assignee: The Scripps Research Institute
    Inventors: Thomas D. Bannister, William R. Roush, Jun Yong Choi, Reji Nair, Andy S. Tsai, Jitendra K. Mishra, John L. Cleveland
  • Patent number: 10323029
    Abstract: The invention provides compounds effective as sphingosine-1-phosphate receptor modulators for treatment of cardiopulmonary diseases, such as hypertension (including malignant hypertension), angina, myocardial infarction, cardiac arrhythmias, congestive heart failure, coronary heart disease, atherosclerosis, angina pectoris, dysrhythmias, cardiomyothopy (including hypertropic cardiomyothopy), heart failure, cardiac arrest, bronchitis, asthma, chronic obstructive pulmonary disease, cystic fibrosis, croup, emphysema, pleurisy, pulmonary fibrosis, pneumonia, pulmonary embolus, pulmonary hypertension, mesothelioma, ventricular conduction abnormalities, complete heart block, adult respiratory distress syndrome, sepsis syndrome, idiopathic pulmonary fibrosis, scleroderma, systemic sclerosis, retroperitoneal fibrosis, prevention of keloid formation, or cirrhosis.
    Type: Grant
    Filed: September 28, 2015
    Date of Patent: June 18, 2019
    Assignee: The Scripps Research Institute
    Inventors: Edward Roberts, Hugh Rosen, Mariangela Urbano, Miguel A. Guerrero
  • Publication number: 20190167604
    Abstract: Arylfluorosulfate compounds derived from anticancer drugs are disclosed herein, which exhibit improved anti-cancer cell proliferation activities compared to their phenolic drug precursors. Among these compounds, the fluorosulfate derivative of fulvestrant showed significantly enhanced activity to down-regulate estrogen receptor (ER) expression in ER+ breast cancer cell line MCF-7, and oral availability in vivo; the fluorosulfate derivative of combretastatin A4 exhibited a 70-fold increase in potency in the drug resistant colon cancer cell line HT-29; and the fluorosulfate derivative of ABT-751 showed enhanced activity relative to ABT-751.
    Type: Application
    Filed: January 9, 2019
    Publication date: June 6, 2019
    Applicant: THE SCRIPPS RESEARCH INSTITUTE
    Inventors: Jie LI, Zilei LIU, Suhua LI, Peng WU, K. Barry SHARPLESS
  • Patent number: 10308912
    Abstract: The present invention generally provides methods and compositions for transdifferentiation of an animal cell from a first non-pluripotent cell fate to a second non-pluripotent cell fate. Also provided are methods and compositions for the transdifferentiation of an animal cell from a non-pluripotent mesodermal, endodermal, or ectodermal cell fate to a different non-pluripotent mesodermal, endodermal, or ectodermal cell fate.
    Type: Grant
    Filed: December 12, 2016
    Date of Patent: June 4, 2019
    Assignee: The Scripps Research Institute
    Inventors: Jem A. Efe, Janghwan Kim, Saiyong Zhu, Simon Hilcove, Sheng Ding
  • Patent number: 10273279
    Abstract: The present invention provides novel PAR1 derived cytoprotective oligopeptides or polypeptides which typically contain at least the first 4 N-terminal residues that are substantially identical to the corresponding N-terminal residues of Met1-Arg46 deleted human PAR1 sequence. These cytoprotective oligopeptides or polypeptides are capable of activating PAR1 and promoting PAR1 cytoprotective signaling activities. The invention also provides engineered cells or transgenic non-human animals which harbor in their genome an altered PAR1 gene that is resistant to cleavage at Arg41 and/or Arg46 residues. Additionally provided in the invention are methods of screening candidate compounds to identity additional cytoprotective compounds or cytoprotective proteases. The invention further provides therapeutic use or methods of employing a PAR1 derived cytoprotective oligopeptide or polypeptide to treat conditions associated with tissue injuries or undesired apoptosis.
    Type: Grant
    Filed: March 27, 2017
    Date of Patent: April 30, 2019
    Assignee: The Scripps Research Institute
    Inventors: Laurent O. Mosnier, John H. Griffin
  • Patent number: 10241011
    Abstract: The invention provides methods and devices for preparing frozen vitrified samples for transmission electron microscopy. By reducing the volume of sample from microliter scale to picoliter scale, the requirement for blotting of excess fluid is minimized or eliminated.
    Type: Grant
    Filed: July 11, 2017
    Date of Patent: March 26, 2019
    Assignees: The Scripps Research Institute, Engineering Arts LLC
    Inventors: Bridget Carragher, Clinton S. Potter, Tilak Jain, Peter Kahn, Peter Wiktor
  • Patent number: 10239934
    Abstract: The invention provides a method for obtaining a broadly neutralizing antibody (bNab), including screening memory B cell cultures from a donor PBMC sample for neutralization activity against a plurality of HIV-1 species, cloning a memory B cell that exhibits broad neutralization activity; and rescuing a monoclonal antibody from that memory B cell culture. The resultant monoclonal antibodies are characterized by their ability to selectively bind epitopes from the Env proteins in native or monomeric form, as well as to inhibit infection of HIV-1 species from a plurality of clades. Compositions containing human monoclonal anti-HIV antibodies used for prophylaxis, diagnosis and treatment of HIV infection are provided. Methods for generating such antibodies by immunization using epitopes from conserved regions within the variable loops of gp120 are provided. Immunogens for generating anti-HIV1 bNAbs are also provided. Furthermore, methods for vaccination using suitable epitopes are provided.
    Type: Grant
    Filed: March 12, 2018
    Date of Patent: March 26, 2019
    Assignees: Theraclone Sciences, Inc., International AIDS Vaccine Initiative, The Scripps Research Institute
    Inventors: Po-Ying Chan-Hui, Steven Frey, Ole Olsen, Jennifer Mitcham, Matthew Moyle, Sanjay K. Phogat, Dennis R. Burton, Laura Marjorie Walker, Pascal Raymond Georges Poignard, Wayne Koff, Melissa Danielle De Jean De St. Marcel Simek-Lemos, Stephen Kaminsky
  • Patent number: 10239877
    Abstract: There are disclosed imidazolinopyrimidinone compounds that have activity to induce TRAIL gene expression in macrophages. There is further disclosed a method for treating various cancers comprising administering effective amounts of an imidazolinopyrimidinone having the structure of Formula I herein. The invention is directed, in various embodiments, to a compound and pharmaceutical composition comprising an effective amount of a compound capable of inducing expression of TRAIL gene in cells capable of expressing the TRAIL gene to produce the cytokine TRAIL.
    Type: Grant
    Filed: March 30, 2015
    Date of Patent: March 26, 2019
    Assignee: The Scripps Research Institute
    Inventors: Kim D. Janda, Nicholas T. Jacob, Jonathan W. Lockner